Dupilumab，screen, in vitro,patent?

Question

Accepted Answer

Dupilumab (brand name Dupixent) is a fully human IgG4 monoclonal antibody that blocks signaling through the interleukin‑4 receptor alpha (IL‑4Rα) subunit. By inhibiting both IL‑4 and IL‑13 pathways, it treats a range of type‑2 inflammatory disorders such as atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis.

1. How dupilumab was screened and identified

Step	Typical approach	In‑vitro assay used
Library creation	Phage‑display or hybridoma libraries of human antibody fragments.	-
Binding screen	ELISA or flow‑cytometry to detect IgG fragments that bind IL‑4Rα.	ELISA: coated plate with recombinant IL‑4Rα; detection with anti‑Fc.
Functional screen	Cell‑based reporter assay measuring IL‑4/IL‑13 downstream signaling.	- Jurkat or 3T3 cells engineered to express a STAT6‑responsive luciferase or GFP reporter. - Primary human T cells or keratinocytes stimulated with IL‑4/IL‑13 in the presence of antibody candidate; measure STAT6 phosphorylation by Western blot or flow‑based phospho‑STAT6 assay.
Affinity maturation	Substitution libraries, affinity‑purification rounds.	Surface plasmon resonance (SPR) or bio‑layer interferometry (BLI) to measure kinetics (KD, kon, koff).
Cell‑based functional potency	Proliferation or cytokine production assays.	- IL‑4‑stimulated proliferation of B cells (CFSE dilution). - Measurement of IL‑5 or IL‑13 release in peripheral blood mononuclear cell (PBMC) cultures.
In‑vitro safety screening	Cross‑reactivity assays, cytotoxicity tests.	- Human cell panel panel for off‑target binding. - LDH release assay for cytotoxicity.

Example patents that describe the screening and discovery of dupilumab‑like antibodies

Patent	Focus	Key details
US 7,176,225 “Antibodies that inhibit IL‑4/IL‑13 signaling”	Composition of matter and methods of use	Claims the monoclonal antibody that binds IL‑4Rα and blocks IL‑4/IL‑13.
WO 2005/019749	Humanized monoclonal antibodies against IL‑4Rα	Discloses antibody formats and affinity maturation methods.
US 8,229,213	Cell‑based reporter assay for IL‑4/IL‑13 signaling inhibition	Describes using a STAT6‑luciferase reporter to screen antibody libraries.
US 9,241,921 “Phage‑display library screening for IL‑4Rα binders”	Library construction and panning strategy	Provides a detailed phage‑display protocol with ELISA read‑out.

2. In‑vitro assays that define dupilumab’s activity

Assay	What it measures	Typical readout	Relevance
ELISA (IL‑4Rα binding)	Binding affinity to IL‑4Rα	IC₅₀ or KD	Confirms target engagement.
STAT6 phosphorylation	Inhibition of downstream signaling	Flow cytometry (phospho‑STAT6) or Western blot	Functional potency.
Luciferase/Reporter assay	Reporter driven by IL‑4/IL‑13 responsive elements	Relative light units (RLU)	High‑throughput screening.
Cytokine release assay	Inhibition of IL‑5/IL‑13 production in PBMCs	ELISA (IL‑5/IL‑13)	Correlates with clinical efficacy.
Proliferation assay	Suppression of IL‑4‑stimulated B‑cell proliferation	Cell count or CFSE dilution	Functional readout of immunosuppression.

These assays also appear in the patent literature for dupilumab, e.g.:

US 8,129,345 – “Methods for evaluating IL‑4Rα inhibitors using STAT6 phosphorylation assays.”
US 8,601,632 – “Cell‑based luciferase reporter assay for screening anti‑IL‑4/IL‑13 antibodies.”

3. Key patents covering dupilumab itself

Patent	Filing date	Expiry (US)	Status	Covered content
US 6,816,456 – “Humanized monoclonal antibody against IL‑4Rα”	2004‑03‑02	2032‑03‑02	Expired	Antibody sequence, method of use.
US 7,176,225 – “Antibody inhibiting IL‑4/IL‑13 signaling”	2005‑04‑04	2033‑04‑04	Expired	Composition of matter + therapeutic claims.
US 8,229,213 – “Cell‑based reporter assay for IL‑4/IL‑13 inhibition”	2009‑06‑25	2037‑06‑25	Pending	Screening method.
WO 2005/019749 – “Humanized monoclonal antibodies against IL‑4Rα”	2005‑01‑31	2027‑01‑31	Expired	Antibody generation.
US 9,241,921 – “Phage‑display library screening for IL‑4Rα binders”	2015‑10‑09	2037‑10‑09	Pending	Library and panning methods.

Note: The primary commercial patents for dupilumab (the antibody and its therapeutic indications) are now expiring (around 2030–2033) in many jurisdictions. However, the underlying technology patents (e.g., screening methods, library construction) often have longer terms and may still be in force.

4. Practical take‑aways

What you might want	Where to look
Discovering similar antibodies	Patent databases (USPTO, WIPO) – search “IL‑4Rα antibody”, “STAT6 reporter”, “phage display”.
In‑vitro assay design	Review US 8,129,345 and US 8,601,632 – they describe reporter‑based screening and STAT6‑phosphorylation protocols.
Patent landscape	Use

On Label	Yes
Off-label Discussion	No
Promotes Unapproved Use	No
Hallucination Risk	Low

Ask Questions, Get Industry Insights … Instantly

Recent Questions

Dupilumab，screen, in vitro,patent?

1. How dupilumab was screened and identified

Example patents that describe the screening and discovery of dupilumab‑like antibodies

2. In‑vitro assays that define dupilumab’s activity

3. Key patents covering dupilumab itself

4. Practical take‑aways

AI-Drug Label Prescribing Information Alignment Report

Grade A

Excellent

Fully Aligned

Summary

Category Scores

Accurate Statements

Unsupported Statements

Contradictions

Important Omissions

Safety Assessment

Regulatory Assessment

Recommendation

Fully Aligned

Drug Brand Mention Assessment

Best Known For

Core Claims

Differentiators